Published in J Cardiovasc Pharmacol on May 01, 1999
Peroxisome proliferator-activated receptor gamma ligands inhibit development of atherosclerosis in LDL receptor-deficient mice. J Clin Invest (2000) 5.07
PPARs and molecular mechanisms of transrepression. Biochim Biophys Acta (2007) 2.10
Rosiglitazone attenuates chronic hypoxia-induced pulmonary hypertension in a mouse model. Am J Respir Cell Mol Biol (2009) 1.88
Role of the parasite-derived prostaglandin D2 in the inhibition of epidermal Langerhans cell migration during schistosomiasis infection. J Exp Med (2001) 1.79
PPARs and the cardiovascular system. Antioxid Redox Signal (2009) 1.28
PPARs and lipid ligands in inflammation and metabolism. Chem Rev (2011) 1.06
PGC-1alpha is a key regulator of glucose-induced proliferation and migration in vascular smooth muscle cells. PLoS One (2009) 1.04
Regulator of calcineurin 1 mediates pathological vascular wall remodeling. J Exp Med (2011) 0.90
PPARgamma as a potential therapeutic target in pulmonary hypertension. Ther Adv Respir Dis (2010) 0.87
Peroxisome proliferator-activated receptor γ inhibits pulmonary hypertension targeting store-operated calcium entry. J Mol Med (Berl) (2014) 0.86
Clinical Use of PPARgamma Ligands in Cancer. PPAR Res (2008) 0.84
Thiazolidinediones up-regulate insulin-like growth factor-1 receptor via a peroxisome proliferator-activated receptor gamma-independent pathway. J Biol Chem (2010) 0.81
Effects of low dose pioglitazone on restenosis and coronary atherosclerosis in diabetic patients undergoing drug eluting stent implantation. Yonsei Med J (2013) 0.79
Therapeutic Implications of PPARgamma in Cardiovascular Diseases. PPAR Res (2010) 0.79
Efficacy and safety of low-dose pioglitazone after primary coronary angioplasty with the use of bare metal stent in patients with acute myocardial infarction and with type 2 diabetes mellitus or impaired glucose tolerance. Heart Vessels (2007) 0.77
Rac1 modification by an electrophilic 15-deoxy Δ(12,14)-prostaglandin J2 analog. Redox Biol (2015) 0.77
Peroxisome proliferator-activated receptor agonists (PPARs): a promising prospect in the treatment of psoriasis and psoriatic arthritis. An Bras Dermatol (2014) 0.76
Chronic allograft rejection: A significant hurdle to transplant success. Burns Trauma (2014) 0.75
Cannabinoid Receptor Type 2 (CB2) Dependent and Independent Effects of WIN55,212-2 on Atherosclerosis in Ldlr-null Mice. J Cardiol Ther (2015) 0.75
The possible role of peroxisome proliferator-activated receptor gamma in heart failure. Exp Clin Cardiol (2004) 0.75
Antidiabetic rosiglitazone reduces soluble intercellular adhesion molecule-1 level in type 2 diabetic patients with coronary artery disease. PPAR Res (2008) 0.75
The effect of Chlamydia pneumoniae on the expression of peroxisome proliferator-activated receptor-gamma in vascular smooth muscle cells. Yonsei Med J (2008) 0.75
Scoring system for the preoperative evaluation of metastatic spine tumor prognosis. Spine (Phila Pa 1976) (1990) 3.97
Noninvasive diagnosis of ischemia-induced wall motion abnormalities with the use of high-dose dobutamine stress MRI: comparison with dobutamine stress echocardiography. Circulation (1999) 3.44
Metabolic effects of troglitazone monotherapy in type 2 diabetes mellitus. A randomized, double-blind, placebo-controlled trial. Ann Intern Med (1998) 3.41
Effect of resynchronization therapy stimulation site on the systolic function of heart failure patients. Circulation (2001) 3.25
Incidence and risk factors of vascular dementia and Alzheimer's disease in a defined elderly Japanese population: the Hisayama Study. Neurology (1995) 2.99
Troglitazone inhibits formation of early atherosclerotic lesions in diabetic and nondiabetic low density lipoprotein receptor-deficient mice. Arterioscler Thromb Vasc Biol (2001) 2.85
Noninvasive detection of myocardial ischemia from perfusion reserve based on cardiovascular magnetic resonance. Circulation (2000) 2.49
Survivin promotes cell proliferation in human hepatocellular carcinoma. Hepatology (2000) 2.15
The POU domain transcription factor Brn-2 is required for the determination of specific neuronal lineages in the hypothalamus of the mouse. Genes Dev (1995) 2.11
Nitric oxide activity is deficient in spasm arteries of patients with coronary spastic angina. Circulation (1996) 2.06
Comparison of dobutamine stress magnetic resonance, adenosine stress magnetic resonance, and adenosine stress magnetic resonance perfusion. Circulation (2004) 2.04
High incidence of amplification of the epidermal growth factor receptor gene in human squamous carcinoma cell lines. Cancer Res (1986) 1.98
Remnant lipoprotein levels in fasting serum predict coronary events in patients with coronary artery disease. Circulation (1999) 1.89
Interleukin-10 is an autocrine growth factor for acquired immunodeficiency syndrome-related B-cell lymphoma. Blood (1995) 1.84
Troglitazone inhibits vascular smooth muscle cell growth and intimal hyperplasia. J Clin Invest (1996) 1.78
Expression and function of PPARgamma in rat and human vascular smooth muscle cells. Circulation (2000) 1.73
Peroxisome proliferator-activated receptor activators target human endothelial cells to inhibit leukocyte-endothelial cell interaction. Arterioscler Thromb Vasc Biol (1999) 1.72
Myocardial catecholamine content after heart transplantation. Circulation (1990) 1.69
Survivin initiates cell cycle entry by the competitive interaction with Cdk4/p16(INK4a) and Cdk2/cyclin E complex activation. Oncogene (2000) 1.61
Improvement of endothelial function and insulin sensitivity with vitamin C in patients with coronary spastic angina: possible role of reactive oxygen species. J Am Coll Cardiol (2000) 1.59
Angiotensin II has multiple profibrotic effects in human cardiac fibroblasts. Circulation (2000) 1.58
Survivin initiates procaspase 3/p21 complex formation as a result of interaction with Cdk4 to resist Fas-mediated cell death. Oncogene (2000) 1.54
Total occlusion trial with angioplasty by using laser guidewire. The TOTAL trial. Eur Heart J (2000) 1.54
Retinoids inhibit proliferation of human coronary smooth muscle cells by modulating cell cycle regulators. Arterioscler Thromb Vasc Biol (2001) 1.54
Intracellular energetic units in red muscle cells. Biochem J (2001) 1.53
Circulating levels of secretory type II phospholipase A(2) predict coronary events in patients with coronary artery disease. Circulation (1999) 1.50
Molecular analysis of external genitalia formation: the role of fibroblast growth factor (Fgf) genes during genital tubercle formation. Development (2000) 1.50
Functional gene testing of the Glu298Asp polymorphism of the endothelial NO synthase. J Hypertens (2000) 1.49
The immediate and long-term effect of optimal balloon angioplasty on the absolute coronary blood flow velocity reserve. A subanalysis of the DEBATE study. Doppler Endpoints Balloon Angioplasty Trial Europe. Eur Heart J (2001) 1.42
Fetal aortic isthmus growth and morphology in late gestation. Ultrasound Obstet Gynecol (2002) 1.41
Protein kinase C inhibitors induce apoptosis in human malignant glioma cell lines. FEBS Lett (1994) 1.39
Idiopathic deafness or hearing loss of unknown etiology following discharge from the NICU. Acta Otolaryngol Suppl (1994) 1.39
[Long-term outcome after coronary emergency intervention]. Dtsch Med Wochenschr (2000) 1.38
Peroxisome proliferator-activated receptor-gamma ligands inhibit choroidal neovascularization. Invest Ophthalmol Vis Sci (2000) 1.37
Randomized multicenter comparison of conventional anticoagulation versus antiplatelet therapy in unplanned and elective coronary stenting. The full anticoagulation versus aspirin and ticlopidine (fantastic) study. Circulation (1998) 1.37
Retracted SADS: A new component of Fas-DISC is the accelerator for cell death signaling and is downregulated in patients with colon carcinoma. Nat Med (2001) 1.37
Functional cardiac MR imaging with steady-state free precession (SSFP) significantly improves endocardial border delineation without contrast agents. J Magn Reson Imaging (2001) 1.37
Peroxisome proliferator-activated receptor gamma ligands inhibit retinoblastoma phosphorylation and G1--> S transition in vascular smooth muscle cells. J Biol Chem (2000) 1.36
Parenchymal hyperdensity on computed tomography after intra-arterial reperfusion therapy for acute middle cerebral artery occlusion: incidence and clinical significance. Stroke (2001) 1.34
Angiotensin II induces migration and Pyk2/paxillin phosphorylation of human monocytes. Hypertension (2001) 1.32
PPARgamma and atherosclerosis: effects on cell growth and movement. Arterioscler Thromb Vasc Biol (2001) 1.31
Blood pressure lowering by pioglitazone. Evidence for a direct vascular effect. J Clin Invest (1995) 1.29
Osteopontin is produced by rat cardiac fibroblasts and mediates A(II)-induced DNA synthesis and collagen gel contraction. J Clin Invest (1996) 1.27
Spectrum of clinical phenotypes and gene variants in cardiac myosin-binding protein C mutation carriers with hypertrophic cardiomyopathy. J Am Coll Cardiol (2001) 1.24
Apigenin inhibits growth and induces G2/M arrest by modulating cyclin-CDK regulators and ERK MAP kinase activation in breast carcinoma cells. Anticancer Res (2001) 1.24
Oncostatin-M is an autocrine growth factor in Kaposi's sarcoma. Am J Pathol (1994) 1.23
Investigation of coronary venous anatomy by retrograde venography in patients with malignant ventricular tachycardia. Circulation (2001) 1.22
Assessment of diffuse coronary artery disease by quantitative analysis of coronary morphology based upon 3-D reconstruction from biplane angiograms. IEEE Trans Med Imaging (1995) 1.20
Obstruction of St Jude Medical valves in the aortic position: significance of a combination of cineradiography and echocardiography. J Thorac Cardiovasc Surg (2000) 1.20
Characterization of mucins in human middle ear and Eustachian tube. Am J Physiol Lung Cell Mol Physiol (2001) 1.19
Production of matrix metalloproteinases and tissue inhibitor of metalloproteinases-1 by human brain tumors. J Neurosurg (1994) 1.19
Deficiency in protein L-isoaspartyl methyltransferase results in a fatal progressive epilepsy. J Neurosci (1998) 1.19
Effects of urokinase receptor occupancy on plasmin generation and proteolysis of basement membrane by human tumor cells. Blood (1991) 1.17
Troglitazone inhibits growth of MCF-7 breast carcinoma cells by targeting G1 cell cycle regulators. Biochem Biophys Res Commun (2001) 1.17
Myocardial osteopontin expression is associated with left ventricular hypertrophy. Circulation (1997) 1.15
TNFalpha induces expression of transcription factors c-fos, Egr-1, and Ets-1 in vascular lesions through extracellular signal-regulated kinases 1/2. Atherosclerosis (2001) 1.14
Mitogen-activated protein kinase activation is involved in platelet-derived growth factor-directed migration by vascular smooth muscle cells. Hypertension (1997) 1.14
Antenatal diagnosis of velamentous umbilical cord insertion and vasa previa with color Doppler imaging. Ultrasound Obstet Gynecol (1998) 1.13
Construction of intertypic chimeric dengue viruses exhibiting type 3 antigenicity and neurovirulence for mice. J Virol (1995) 1.13
Comparative analysis of expression of hepatocyte growth factor and its receptor, c-met, in gliomas, meningiomas and schwannomas in humans. Cancer Lett (1998) 1.12
Transvenous biventricular defibrillation halves energy requirements in patients. Circulation (2001) 1.12
The apoptotic regulatory protein ARC (apoptosis repressor with caspase recruitment domain) prevents oxidant stress-mediated cell death by preserving mitochondrial function. J Biol Chem (2001) 1.12
Peroxisome proliferator-activated receptor and retinoid X receptor ligands inhibit monocyte chemotactic protein-1-directed migration of monocytes. Eur J Pharmacol (2000) 1.12
Insulin signaling in the arterial wall. Am J Cardiol (1999) 1.12
Intracerebral hemorrhage in a Japanese community, Hisayama: incidence, changing pattern during long-term follow-up, and related factors. Stroke (1988) 1.12
Hepatocyte growth factor promotes cell survival from fas-mediated cell death in hepatocellular carcinoma cells via Akt activation and Fas-death-inducing signaling complex suppression. Hepatology (2000) 1.12
Expression of c-Met correlates with grade of malignancy in human astrocytic tumours: an immunohistochemical study. Histopathology (1997) 1.11
Should stimulation site be tailored in the individual heart failure patient? Am J Cardiol (2000) 1.11
Effects of lovastatin on progression of non-dilated and dilated coronary segments and on restenosis in patients after PTCA. The cholesterol lowering atherosclerosis PTCA trial (CLAPT). Eur Heart J (1999) 1.10
Processing of chromogranin A by plasmin provides a novel mechanism for regulating catecholamine secretion. J Clin Invest (2000) 1.10
[Policy paper to the cardiac re-sychronization therapy]. Z Kardiol (2003) 1.09
Comparison of magnetic resonance real-time imaging of left ventricular function with conventional magnetic resonance imaging and echocardiography. Am J Cardiol (2001) 1.08
Angiotensin II directly increases transforming growth factor beta1 and osteopontin and indirectly affects collagen mRNA expression in the human heart. Cardiovasc Res (2000) 1.07
TAG-1-deficient mice have marked elevation of adenosine A1 receptors in the hippocampus. Biochem Biophys Res Commun (2001) 1.07
Role of the medulla oblongata in plateau-wave development in dogs. J Neurosurg (1987) 1.07
Accuracy of diagnosis on death certificates for underlying causes of death in a long-term autopsy-based population study in Hisayama, Japan; with special reference to cardiovascular diseases. J Clin Epidemiol (1989) 1.07
Control of vascular cell proliferation and migration by PPAR-gamma: a new approach to the macrovascular complications of diabetes. Diabetes Care (2001) 1.07